Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial. (2022)
Attributed to:
Developing Existing Healthcare Technologies to Deliver More Affordable and Effective Cancer Care
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1200/jco.21.00728
PubMed Identifier: 34757812
Publication URI: http://europepmc.org/abstract/MED/34757812
Type: Journal Article/Review
Volume: 40
Parent Publication: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Issue: 8
ISSN: 0732-183X